Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
26 pending office actions • 19 art units • 24 examiners • 0 of 26 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
The University of Toledo maintains 25 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is spread across 23 distinct examiners, suggesting a prosecution strategy where 25 pending office actions are handled by 23 distinct examiners. Such a distribution requires the university to manage numerous simultaneous dialogues across the patent office. Practitioners must be prepared to navigate the individual preferences of 23 distinct examiners.
The portfolio's reach extends across 18 distinct art units, reflecting the technical scope of its biotechnology and pharmaceutical filings. ALYSSA G WESTON is the busiest examiner, managing 2 busiest examiner pending actions. This count of 2 busiest examiner pending actions is the highest for any single examiner in the portfolio. With 18 distinct art units involved, the university's prosecution efforts are active across many different units, indicating a range of inventions within the Biotechnology & Pharmaceuticals field. This variety of art units suggests a decentralized intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (8%) |
| §103 only | 8 (31%) |
| §112 only | 2 (8%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 1 (4%) |
| Multi-statute (no §101) | 12 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 2 | 59.8% | +50.9% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| MILO, MICHAEL | 1 | 50.8% | +52.5% |
| BURKE, MATTHEW RYAN | 1 | 0.0% | +0.0% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| HOWELL, GWYNNETH LINNEA | 1 | 44.4% | +79.2% |
| SPIES, BRADLEY R | 1 | 74.2% | +20.5% |
| MCEVOY, THOMAS M | 1 | 70.8% | +35.5% |
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274549 | C PRIME AGENTS FOR TREATING METABOLIC DISORDERS | BRAUN, MADELINE E | 12d |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 28d |
| 17859260 | THREE-WAY UROLOGY CATHETER STOPCOCK AND UROLOGY CATHETER STOPCOCK ASSEMBLY | PATEL, SHEFALI DILIP | 54d |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | MACH, ANDRE | 70d |
| 18746938 | FLUSHABLE WET WIPES | BURKE, MATTHEW RYAN | — |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | — |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | — |
| 18606189 | Automatic Fraction Collector | SPIES, BRADLEY R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18951851 | Modular Hip Distractor | MILO, MICHAEL | 16d overdue |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 28d |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | MACH, ANDRE | 70d |
| 18971862 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | WESTON, ALYSSA G | — |
| 18931782 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | WESTON, ALYSSA G | — |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | — |
| 18670112 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | JACKSON-TONGUE, LAKIA J | — |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1675 | 2 |
| 3786 | 1 |
| 1619 | 1 |
| 1645 | 1 |
| 3774 | 1 |
| 1621 | 1 |
| 1615 | 1 |
| 3771 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971862 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | WESTON, ALYSSA G | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18951851 | Modular Hip Distractor | MILO, MICHAEL | 3786 | §103 | Non-Final OA | 16d overdue | Pending | Nov 19, 2024 |
| 18931782 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | WESTON, ALYSSA G | — | DP | Non-Final OA | — | Pending | Oct 30, 2024 |
| 18746938 | FLUSHABLE WET WIPES | BURKE, MATTHEW RYAN | 1619 | §103 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | 1641 | §101§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18670112 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | JACKSON-TONGUE, LAKIA J | — | §112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | — | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18606189 | Automatic Fraction Collector | SPIES, BRADLEY R | 1645 | §103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18688151 | SIZE ADJUSTABLE AORTIC ENDOGRAFT FENESTRATION DEVICE AND RETRIEVABLE VESSEL MARKER | MCEVOY, THOMAS M | 3774 | §102§103 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | SCHMIDT, IZABELA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | MACH, ANDRE | 1615 | §103§112 | Non-Final OA | 70d | Pending | Jan 19, 2024 |
| 18580987 | SOLID PHANTOM DEVICE FOR BEAM SCANNING | MALEVIC, DJURA | — | §103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18410384 | AORTIC PUNCH | DANG, ANH TIEU | 3771 | §103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18506571 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | LI, RUIXIANG | 1674 | §102§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18557651 | METHODS OF TREATING CANCER AND ISCHEMIA DISEASES BY INHIBITION AND INTERVENTION OF ATR PROLYL ISOMERIZATION | SEAMAN, D MARGARET M | 1625 | §102§103 | Final Rejection | — | Pending | Oct 27, 2023 |
| 18274549 | C PRIME AGENTS FOR TREATING METABOLIC DISORDERS | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | 12d | Pending | Jul 27, 2023 |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | 28d | Pending | Jul 17, 2023 |
| 18038053 | QUANTIFICATION OF SPERM CENTRIOLE QUALITY | BORGEEST, CHRISTINA M | 1675 | §101§103 | Final Rejection | — | Pending | May 22, 2023 |
| 18314240 | OSTEOANABOLISM BY 14-3-3ZETA | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Final Rejection | — | Pending | May 09, 2023 |
| 18101812 | Aspiration Catheter with an Adjustable Tip for the Intracranial Circulation | SMITH, PETER DANIEL | 3781 | §102§103 | Final Rejection | — | Pending | Jan 26, 2023 |
| 18093057 | ANTIMICROBIAL FILTRATION | HORGER, KIM S. | 1784 | §103 | Final Rejection | 46d overdue | Pending | Jan 04, 2023 |
| 17859260 | THREE-WAY UROLOGY CATHETER STOPCOCK AND UROLOGY CATHETER STOPCOCK ASSEMBLY | PATEL, SHEFALI DILIP | 3783 | §103§112 | Non-Final OA | 54d | Pending | Jul 07, 2022 |
| 17775932 | Methods and Kits using Internal Standards to Control for Complexity of Next Generation Sequencing(NGS) Libraries | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | 36d overdue | Pending | May 11, 2022 |
| 17737325 | Emulsion Formation Assisted by Corona Discharge and Electrohydrodynamic Pumping | BRAZIN, JACQUELINE | 1798 | §103 | Final Rejection | 27d | Pending | May 05, 2022 |
| 17178455 | SUPER SENSITIVE SENSOR FOR THE DETECTION OF HYDROXYL FREE RADICALS WITH SCAVENGING PROPERTIES | SUN, CAITLYN MINGYUN | 1795 | §103 | Non-Final OA | 1d overdue | Pending | Feb 18, 2021 |
| 18723526 | METHODS AND SYSTEMS FOR EVALUATING FIBER QUALITIES | AHMED, JAMIL | 2872 | §103 | Non-Final OA | — | Pending | Jun 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial